The global spinal pumps market was valued at USD 222.0 million in 2015. The increasing prevalence of movement disorders, such as multiple sclerosis, cerebral palsy, and spinal and brain injuries, and the resultant corresponding demand for long-term therapy, involving the spinal pump devices for chronic pain management in the aforementioned target disorders, are anticipated to widen the base for the spinal pumps market over the forecast period.
Moreover, as a consequence of the expanding geriatric population, characterized with a higher susceptibility to developing the above-mentioned diseases, is further presumed to increase the demand for spinal pumps throughout the forecast period.
North America spinal pumps market share, by application, 2013 - 2024 (USD Million)
With the advent of technological innovations, such as the incorporation of programmable external devices with pumps that facilitate controlled release of low medication dosages is presumed to accelerate the demand for these pain relieving solutions. Moreover, these advancements have resulted in the development of intrathecal pumps, which have achieved significantly minimizing, the occurrence of adverse events typically observed with intravenous and oral drug administration routes; the higher drug efficacy attained with sustained release of smaller drug doses through these spinal pumps is expected to provide lucrative growth opportunities for the industry in the near future.
These advanced solutions for long-standing pain are based on innovative technologies including targeted drug delivery systems (DDS) that enable effective targeting of pain, micro-dose infusions that engender reduced drug pharmacodynamics effects, and patient-controlled devices that empower patients with greater control over their treatment. The associated benefits comprising faster recovery rates and an improved safety profile of the aforementioned innovations resulted in better patient outcomes, which are anticipated to drive patient and physician preference for these devices in the future.
Low patient compliance, the high long-term associated costs, and the rising cases of relapse associated with conventional medication methods used in the treatment of spasticity and chronic pain is expected to present the spinal pumps market with a high growth potential during the forecast period.
The pain management segment held a substantial industry share of over 69.0% in 2015 as a consequence of the presence of a relatively large patient base suffering from chronic pain, as a consequence of the failed clinical outcomes suffered through other treatments methods.
According to American Academy of Pain Management, chronic pain is exceedingly prevalent; approximately 20% to 30% of the general population is afflicted with it wherein 2/3 of these patient’s experience pain for a long time span of more than 5 years. This aforementioned factor is responsible for propelling the demand and thus contributing towards the overall market share of intrathecal pumps.
The non-malignant pain category dominated the overall pain management segment due largely to it being the major burden globally and as a result held a share of over 75% in the year, 2015. Additionally, the numerous initiatives that are directed at evaluating the current drug panel employed in pain treatments to negate the related adverse effects and providing guidance over the existent treatments methods to alleviate chronic non-malignant pain syndromes, such as by the Pain and Palliative Care Practice and Research Network, is anticipated to further facilitate the penetration of the spinal pump devices in the industry.
Spasticity management is anticipated to grow exponentially at a CAGR throughout the forecast period. The exponential growth can be attributed to the rising incidences of movement and neurological disorders coupled with the fact that fewer effective treatment options are available for spasticity. According to University of Washington Rehabilitation Medicine, Northwest Regional Spinal Cord Injury System, spasticity occurs in approximately 78% of the patients suffering from spinal cord injuries. In addition, around 80 percent of the patient base with cerebral palsy (CP) most often suffers with CP-related spasticity to a certain degree. The aforementioned statistics exhibit the clinical urgency to treat spasticity thus impelling the industry demand during the forecast period.
In 2015, North America held a substantial share of the regional spinal pumps market, with a share of over 54.0%. The presence of clearly defined reimbursement models in this region and the efficient regulatory framework increasingly emphasizing on patient safety as one of their primary objectives in addition to maintaining high treatment efficacy standards are expected to drive the demand for the devices in this region.
The Asia Pacific spinal pumps market is anticipated to grow at the fastest CAGR of over 6.0% during the forecast period owing to the rapidly improving healthcare infrastructure and the increasing patient awareness levels towards alternative treatment options. The growth can be attributed to the multitude of investments deployed by prominent industry players to improve the present healthcare infrastructure, which is expected to intensify the growth of the hospital equipment segment in the fast emerging economies, such as China and India.
Furthermore, the increasing number of collaborations between private insurance companies and the government is gradually improving the overall healthcare coverage to ensure enhanced patient accessibility to better healthcare facilities; this in turn is anticipated to provide the region with a high growth potential.
Some leading players operating in the spinal pumps market include DePuy Synthes, FlowonixMedical, Inc., Medtronic Plc, Tricumed Medizintechnik GmbH, and Teleflex, Inc. These industry players are undertaking strategies, such as entering into mergers and acquisitions, product launches, and geographical expansions, to capture a larger share of the industry.
For instance, in January 2015, Flowonix Medical, Inc. announced the FDA approval for its next generation intrathecal infusion device, Prometra II. This launch was carried out to expand their targeted drug delivery solutions in order to strengthen its current product portfolio and to capture a greater industry share. Furthermore, the developing number of pipeline products is a consequence of the high R&D investment strategies employed by these companies.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."